Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
Swiss pharma giant Novartis NVS announced an agreement to acquire privately held UK-based biotechnology company Myricx Bio, which…
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics buyout, sending the molecule to…
Roche axes 4 Chugai solid tumor assets in early-phase clear-out
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this…
Roche returns to MediLink with $570M near-term payments for ADC
Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner…
Novartis nixes 6 ph. 1 assets, adds 2 new cancer candidates
Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. The…
Novartis jettisons ph. 1 cancer candidate after 0% efficacy
Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30…
Roche offloads clinical-phase cancer drug to Celleron
Roche has offloaded its anti-CSF1R monoclonal antibody emactuzumab to Celleron Therapeutics. The licensing deal comes almost two years…